Article Text

Download PDFPDF
ICON 2020—International Scientific Tendinopathy Symposium Consensus: the development of a core outcome set for gluteal tendinopathy
  1. Angela M Fearon1,2,
  2. Alison Grimaldi3,4,
  3. Rebecca Mellor3,5,
  4. Anthony Michael Nasser6,
  5. Jane Fitzpatrick7,8,
  6. Andreas Ladurner9,
  7. The COS-GT consensus group,
  8. Bill Vicenzino10
    1. 1 Faculty of Health, University of Canberra Research Institute for Sport and Exercise, Bruce, Australian Capital Territory, Australia
    2. 2 Trauma and Orthopaedic Research Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia
    3. 3 University of Queensland Physiotherapy, St Lucia, Queensland, Australia
    4. 4 PhysioTec Physiotherapy, Brisbane, Queensland, Australia
    5. 5 Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia
    6. 6 University of Technology Sydney, Broadway, New South Wales, Australia
    7. 7 The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
    8. 8 Research Committee, Australasian College of Sport and Exercise Physicians, Melbourne, Victoria, Australia
    9. 9 Orthopaedics and Traumatology, Kantonsspital St Gallen, Sankt Gallen, Switzerland
    10. 10 Physiotherapy, The University of Queensland, Saint Lucia, Queensland, Australia
    1. Correspondence to Dr Angela M Fearon, Faculty of Health, University of Canberra Research Institute for Sport and Exercise, Bruce, ACT 2617, Australia; Angie.Fearon{at}Canberra.edu.au

    Abstract

    Gluteal tendinopathy (GT) is common and can be debilitating and challenging to manage. A lack of condition specific and appropriate outcome measures compromise evidence synthesis for treatment and limits clinical guideline development. Our objective was to develop a core outcome measurement set for GT (COS-GT). Participants were patients with GT and expert health professionals (HPs). A scoping review identified measures used in GT research, which were mapped to the nine International Scientific Tendinopathy Symposium Consensus core domains, and included in two surveys of HPs. The first survey identified the feasible and true measures for each domain. The second survey refined the list which a patient focus group then considered. Meeting online, HPs reached consensus (agreement ≥70%) on the most appropriate COS-GT measures. 34 HPs and seven patients were recruited. 57 measures were mapped to the nine core domains. Six measures did not proceed past survey one. Of those that progressed, none had adequate clinimetric properties for a COS-GT. Thus, participants decided on interim measures: the global rating of change, pain at night, time to pain onset with single limb stance, pain with stair walking, pain self-efficacy and hip abduction strength. HP participants additionally recommended that pain over the last week, the European Quality of Life-5 dimensions-5 levels and the Victorian Institute of Sport Assessment-Gluteal be considered in clinical trials, as they currently provide best easures of the relevant tendinopathy domains. In conclusion this interim COS-GT should guide outcome measure selection in clinical practice and future research trials in patients with GT.

    • Hip
    • Tendinopathy
    • Consensus
    • Women
    • Weights and Measures

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • AMF and AG are joint first authors.

    • Twitter @AngieFearon, @alisongrimaldi, @TonyNasserPT, @sportsdocaus, @Bill_Vicenzino

    • AMF and AG contributed equally.

    • Correction notice This article has been corrected since it published Online First. The collaborator information has been updated.

    • Collaborators The COS-GT consensus group. Jane Andreasen; Paul Barrett; Ettore Carlisi; Chris Clifford; Jill Cook; Delphine Courvoisier; Stephanie Di Stasi; Jay Ebert; Helen French; Jamie Gaida; Charlotte Ganderton; Michelle Hall; Jens Erik Jorgenson; Carston Mølgaard; Nicola Maffulli; Neal L Miller; Katie Mornington; John O’Donnell; Yong Hao Pua; Jennie Scarvell; Adam Semciw; Alison Smeatham; Wayne Spratford; Gareth Stephens; Mathieu Thaunat; Michael Whitehouse; Stephanie Woodley.

    • Contributors Conceived project: AMF, AG, RM, BV. Design of project: AMF, AG, RM, BV, JF and AL. Coordination of project: AMF, AG, RM, BV. Contributed data: entire author group. Data analysis: AMF, AG, RM, BV, AMN. Data interpretation: entire author group. Wrote the paper: entire author group.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.